The global liquid biopsy market is anticipated to grow at a significant CAGR of 17.3% during the forecast period. The liquid biopsy diagnosis has been driven by several factors, and one of them is the advantages it offers over the other process. Liquid biopsy is a process that requires body liquid. There are several body fluids that contain genetic material derived from tumors such as urine, saliva, stool, blood, and cerebrospinal fluid (CSF). The main advantages of liquid biopsies are:
To learn more about this report request a sample copy @ https://www.omrglobal.com/industry-reports/liquid-biopsy-market
- Minimally invasive
- Low risk
- High throughput
- Rapid
- Real-time
These advantages help in Identifying targeted treatments and clinical trial eligibility for patients. It informs which tissue-based testing is not appropriate or is not available, liquid biopsy can offer a safe alternative test for determining targeted therapy or eligibility for inclusion in clinical trials.
Moreover, it also helps in monitoring the treatment or disease with its minimally invasive, rapid, and economical test which provides real-time information about a tumor. With all these advantages this process has been projected to grow significantly during the forecast period.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Biomarker Type
- By Cancer Type
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- including Bio-Rad Laboratories Inc., CellMax Life, Guardant Health Inc., MDxHealth SA, QIAGEN NV, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
O Deviation from the pre-COVID-19 forecast
O Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Liquid BiopsyMarket Report Segment
By Biomarker Type
- Circulating Tumor Cells
- Circulating Tumor DNA (ctDNA)
- Others (Extracellular Vesicles)
By Cancer Type
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Other Cancers
By End-User
- Hospitals and Laboratories
- Academic and Research Centres
A full report of Liquid Biopsy Market is available at: https://www.omrglobal.com/industry-reports/liquid-biopsy-market
Liquid Biopsy Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Biocept Inc.
- Biodesix, Inc.
- Circulogene
- Clearbridge Biomedics Pte Ltd.
- Cynvenio Biosystems, Inc.
- Epigenomics AG
- Exosome Diagnostics Inc.
- Hoffmann-La Roche AG
- Genomic Health Inc.
- Inivata Ltd.
- Lariat Biosciences, Inc.
- Menarini-Silicon Biosystems
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
